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Multiple sclerosis (MS) is a disease of the central nervous system in which immune mediated 
damage to myelin is characteristic. For an overview of this condition and its pathophysiology, 
please refer to one of many excellent published reviews (Sorensen and Ransohoff, 1998; Weiner, 
2009). To follow, is a discussion focused on the possibility that synaptic injury occurs in at least 
a subset of patients, and that matrix metalloproteinases (MMPs) play a role in such.
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recent MRI study showed that neocortical atrophy occurred in the 
earliest stages of MS and that it was significant even with minimal 
white matter damage (Iimuro et al., 2003).
Neocortical lesions have been linked to axonal, neuronal, and 
glial loss (Vercellino et al., 2005; Wegner et al., 2006). Such lesions 
have also been associated with synaptic elimination. For example, 
a 47% decrease in neocortical synaptophysin was noted in one 
study, and the authors concluded that neocortical lesions might 
make a major independent contribution to MS pathology (Wegner 
et al., 2006).
Synaptic damage also occurs in experimental allergic encepha-
lomyelitis (EAE), an animal model of autoimmune demyelina-
tion. Analysis of synaptic protein abundance in EAE brains reveals 
reduced levels of the pre-synaptic proteins synaptophysin and syn-
apsin, and reduced levels of the post-synaptic protein PSD-95. The 
synaptic injury was linked to infiltrating inflammatory cells (Zhu 
et al., 2003). The authors of this study hypothesized that disease 
associated changes in intracellular calcium might have activated the 
intracellular protease calpain, which is known to target PSD-95 (Lu 
et al., 2000). In related work, synaptic stripping was described in 
association with focal cortical inflammation initiated by the intrac-
erebral injection of killed bacteria (BCG). In this model, axosomatic 
synapses were displaced by activated microglia (Trapp et al., 2007). 
A summary of relevant studies is shown in Table 1.
Matrix Metalloproteases- a faMily of zinc 
dependent endopeptidases that can target varied 
synaptic substrates
MMps- an overview
MMPs are a family of zinc dependent endopeptidases, of which are 
found in humans. Subsets include the soluble MMPs, at least some 
of which may be released from vesicular stores. These forms contain 
a pro- domain, a catalytic domain, and typically, a   hemopexin like 
architecture of the central synapse
Synapses are highly dynamic structures through which neurons 
communicate. Distal terminals of an axon make up the pre-syn-
aptic component of the synapse, while actin rich dendritic spines 
constitute the post-synaptic component. The action potential is 
propagated along the axon to terminals, and subsequent changes 
in intracellular calcium lead to the release of neurotransmitter 
containing vesicles. Released neurotransmitter crosses the synap-
tic cleft and binds to specific receptors which are concentrated 
on dendritic spines. As synapses become stronger, the diameter of 
dendritic spines may concomitantly enlarge to allow for increased 
insertion of neurotransmitter receptors.
Synaptic structure is organized through a sequential program 
that involves specific protein-protein and protein-lipid interac-
tions. While a full discussion of synapse development is beyond 
the scope of this review, it should be noted that synaptic cell 
adhesion molecules (CAMs) may contribute to this process. These 
molecules can also influence the structure and function of pre-
formed synapses. CAMs include cadherins, neurexins, neuroli-
gins, integrins, and immunoglobulin (Ig) superfamily molecules 
(IgCAMs). Of additional relevance to this review are specific pre- 
and post-synaptically localized proteins. Immunostaining can be 
used to visualize these molecules which including the   pre-synaptic 
protein synaptophysin, and the post-synaptic density protein 
PSD-95.
synaptic injury and Ms
Cognitive impairment may occur in association with MS (Gonzalez-
Rosa et al., 2006; Schulz et al., 2006). Multiple mechanisms may 
contribute, including axonal transection (Trapp et al., 1998) and 
diffuse white matter damage that impairs the connectivity of large 
scale networks (Audoin et al., 2006; Ranjeva et al., 2006). Gray 
matter damage may, however, also be important. For example, a Frontiers in Psychiatry  |  Neurodegenerative Diseases    October 2010  | Volume 1  | Article 130  |  2
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MMps can cleave a variety of synaptic proteins
In terms of synaptic substrates, synaptic CAMs may be of par-
ticular relevance. Given what is known about MMP substrates 
in extra CNS sites, MMPs may be relatively efficient in terms of 
their ability to process such molecules. For example, MMPs have 
been well studied for their role in cell migration, and it is thus 
  intuitive that processing of CAMs would play an important role 
in this process. Numerous studies support this possibility. For 
example, metalloproteinase mediated shedding of soluble ICAM-1 
has been demonstrated (Lyons and Benveniste, 1998), and soluble 
ICAM-1 has been shown to promote smooth muscle cell migra-
tion (Lee et al., 2008).
Another important reason to focus on the potential for MMPs 
to mediate CAM cleavage in the setting of a disease that includes 
synaptic injury, however, lies in an abundance of evidence sug-
gesting that CAMs are critical to synaptic structure and function 
(Sakurai et al., 1998). And though unrelated to synaptic injury 
per se, it is worth mentioning that CAM family members such as 
SynCAM4 might also mediate axon-glial interactions critical to 
processes including remyelination (Spiegel et al., 2007).
Synaptic CAMs have been shown to influence neuronal cell 
migration (Takeuchi and O’Leary, 2006), dendrite morphology 
(Tian et al., 2007), and the genesis/formation of the excita-
tory/inhibitory pre-synaptic complex (Biederer et al., 2002). 
Varied studies have also shown CAM integrity influences long 
term potentiation (LTP), a potential measure of learning and 
memory (Benson et al., 2000). It is therefore likely that metal-
loproteinase dependent processing of CAMs will likely have 
effects on both the   formation and function of the synapse. In 
support of this possibility is a recent study which showed that 
ICAM-5 cleavage was linked to changes in dendrite morphology 
(Tian et al., 2007). This study was focused on MMP-2 and -9, 
MMPs which are elevated in MS as will be discussed in a sec-
tion to follow. We also observed that varied MMPs could cleave 
ICAM-5 from hippocampal neurons, and that this could occur 
within 5 min of cell stimulation with NMDA (Conant et al., 
2010). Rapid cleavage suggests that MMPs might be released 
from preformed neuronal stores to rapidly modulate synaptic 
protein integrity.
domain. The latter may play a role in binding interactions. Activation 
of secreted soluble MMPs can occur secondary to shedding of the 
pro- domain, or secondary to events which influence tertiary struc-
ture such as oxidation and nitrosylation. Reductions in soluble MMP 
activity can be affected through binding interactions with endogenous 
inhibitors, or tissue inhibitors of MMPs (TIMPs). While secreted into 
the extracellular space, soluble MMPs can interact with specific cell 
surface molecules in which case their proteolytic activity may be 
relatively localized. In addition, select MMPs, membrane type MMPs 
(MT-MMPs), possess a transmembrane domain, as do the related 
“a disintegrin and metalloproteinase(s)” or ADAMs. Of note, is that 
while named for their ability to target components of the extracel-
lular matrix such as collagen and laminin, MMPs are increasingly 
recognized as effectors of non-matrix proteins. MMPs process soluble 
molecules including chemokines and cytokines, and they also target 
a variety of cell surface receptors and adhesion molecules.
MMPs are expressed in the CNS by a variety of cell types. It has 
been shown, for example, that astrocytes can release MMP-1, -2 
and -3, and that microglia can release MMP-7,-9 and -12 (Yong 
et al., 1998; Conant et al., 1999; Vos et al., 2000). Neurons may also 
release MMPs in the setting of excitotoxic injury (Szklarczyk et al., 
2002; Meighan et al., 2006). MMPs are also released from activated 
monocytes and T cells, with monocytes releasing MMP-1,-7,-9 and 
-12, and T cells releasing abundant quantities of MMP-9. T cells 
also express MT1-MMP, which has proteolytic activity both in its 
membrane associated and shed extracellular domain form (Toth 
et al., 2005).
Of relevance to MS, MMPs have been well studied for their abil-
ity to cleave matrix proteins of the blood brain barrier and thus 
potentially facilitate the CNS ingress of inflammatory molecules 
and/or serum derived toxins (Anthony et al., 1998). MMPs have 
also been studied for their ability to cleave myelin basic protein 
(MBP) and myelin associated glycoprotein (Kieseier et al., 1999; 
Agrawal et al., 2008; Milward et al., 2008), and more recently, to 
generate immunogenic MBP peptides (Shiryaev et al., 2009). Of 
particular relevance to synaptic injury, however, is an emerging 
appreciation of MMPs as molecules that may be released proximal 
to the synapse (Sbai et al., 2008). A summary of relavant synaptic 
substrates is presented in Table 2.
Table 1 | Synaptic injury in MS and relevant disease models.
Disease/Model  Evidence of synaptic injury  Reference(s)
Multiple sclerosis  Axonal transection  Trapp et al. (1998)
Multiple sclerosis  Reduced synaptophysin as measured by immunoautoradiography  Wegner et al. (2006)
EAE  Reduced synaptic density as assessed by Golgi staining and  Rossi et al. (2009) 
  quantification. Exercise ameliorated this effect
EAE  Reduced synaptophysin, synapsin 1 and PSD-95 immunoreactivity  Zhu et al. (2003) 
  that correlated with inflammatory cell infiltration
EAE  Inflammatory cell infiltration with AMPA type glutamate receptor  Centonze et al. (2009) 
  phosphorylation and AMPA receptor-dependent synaptopathy
EAE   Alterations in excitatory transmission as determined by excitatory  Centonze et al. (2007) 
  post-synaptic potential (EPSP) recordings
Focal cortical inflammation via   Synaptic stripping/microglial cell infiltration of synaptic space  Trapp et al. (2007) 
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(AMPA) receptor subunits (Cho et al., 2008). Thus, from these 
studies, MMPs might dampen glutamate transmission, something 
that could be protective in the setting of acute inflammation.
Additional synaptic modulators that may be processed by MMPs 
include G protein coupled receptors of the proteinase activated 
receptor family (Boire et al., 2005). Activation of these receptors 
follows from cleavage of the N terminus and the subsequent expo-
sure of a tethered peptide ligand. These receptors are abundantly 
expressed on neurons (D’Andrea et al., 1998; Wang and Reiser, 
2003) and their activation could potentially modulate synaptic 
structure and function.
MMp-dependent processing of synaptic substrates plays an 
iMportant role in norMal synaptic physiology
While a relatively new area of investigation, published studies sug-
gest that MMPs may play a critical role in learning and memory. 
For example, a broad spectrum MMP inhibitor has been shown 
to reduce multiple forms of hippocampal CA1 plasticity (Meighan 
et al., 2007), and MMP-9 activity has been implicated in the main-
tenance of late LTP (Nagy et al., 2006). In addition, antisense to 
MMPs has been shown to prevent acquisition in the Morris water 
maze test (Meighan et al., 2006), and methamphetamine-induced 
behavioral sensitization is reduced in mice lacking MMP-2 or 
MMP-9 (Mizoguchi et al., 2007). Similarly, proteases have been 
shown to contribute to cocaine associated conditioned place pref-
erence (Brown et al., 2007, 2008; Maiya et al., 2009). In a more 
recent study, it was shown that a broad spectrum MMP inhibi-
tor could prevent reconsolidation of a fear association memory 
that was not dependent on contextual cues (Brown et al., 2009). 
The mechanisms by which MMPs are important to learning and 
memory are as yet unclear, though we and others have suggested 
ICAM-5 is but one of several synaptic CAMs that may be tar-
geted by MMPs. For example, work from the laboratory of Patricia 
Maness has shown that MMPs can cleave NCAM (Hinkle et al., 
2006), a molecule that may play a role in synapse formation (Muller 
et al., 2010). Others have shown that MMPs can process cadher-
ins including N-cadherin and E-cadherin (Monea et al., 2006). 
N-cadherin has been linked to varied effects on the synapse. It can 
influence synaptic vesicle clustering (Stan et al., 2010), LTP (Tang 
et al., 1998; Bozdagi et al., 2000), and dendritic spine morphogen-
esis (Togashi et al., 2002). MMPs have also been shown to target 
synaptic dystroglycan (Michaluk et al., 2007), and though of less 
relevance to the CNS, agrin (VanSaun and Werle, 2000).
Though future studies will determine the extent to which MMPs 
target synaptic CAMs in MS and EAE, at least one study has shown 
that CAM levels may be reduced in the latter. This study showed 
that levels of NCAM-1 were reduced in CA1 and CA3 regions of 
the hippocampus, while levels of MMPs -2 and -9 were increased 
in the same (Jovanova-Nesic and Shoenfeld, 2006).
While a variety of synaptic CAMs may be susceptible to MMP 
mediated proteolysis, additional synaptic proteins might be proc-
essed as well. For example, two studies have shown that MMPs can 
process the NR1 subunit of the N-methyl-d-aspartate (NMDA) 
type glutamate receptor (Pauly et al., 2008; Szklarczyk et al., 2008). 
These studies were focused on MMP-3 and -7, MMPs that have a 
relatively broad spectrum of substrates and that may be released 
by activated glia in the context of CNS inflammation. It was also 
shown that MMP-7 mediated cleavage of NR1 was associated 
with a reduction in NMDA stimulated calcium flux (Szklarczyk 
et al., 2008). In another study, it was shown that a transmembrane 
MMP could cleave neuronal pentraxin to affect an internaliza-
tion  of  α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate 
Table 2 | Synaptic proteins that are processed by MMPs.
Substrate Protease Relevance to synaptic structure/function Reference(s)
N-cadherin MT5-MMP
MMP-7
ADAM-10
Synapse formation and plasticity Williams et al. (2010), Monea et al. (2006), 
Kohutek et al. (2009)
Telencephalin/
ICAM-5
MMP-2, -3, -7 , -9 Shedding is associated with changes in dendritic spine 
morphology and may play a role in select forms of plasticity
Conant et al. (2010), Tian et al. (2007)
NR1 MMP-3
MMP-7
Obligate subunit of the NMDA type glutamate receptor Pauly et al. (2008), Szklarczyk et al. (2008)
NR2A MMP-7 Subunit of the NMDA type glutamate receptor Szklarczyk et al. (2008)
Neuronal pentraxin 
receptor (NPR)
ADAM-17 Ectodomain shedding allows an N terminal fragment to 
surround and internalize AMPA type glutamate receptors, 
thus contributing to synaptic plasticity/long term depression
Cho et al. (2008)
SNAP-25 MMP-7 Synaptic vesicle/neurotransmitter release Szklarczyk et al. (2007b)
Pro-BDNF MMP-3
MMP-7
Effector of neuronal survival and synaptic plasticity Lee et al. (2001)
IGFBP-6 MMP-9
MMP-12
IGFBP-6 may sequester IGF , a potent effector of neuronal 
survival and a potential contributor to synapse formation
Larsen et al. (2006)
Brevican MMP-9 Structural stability of the synapse. Proteolytic cleavage has 
been associated with synaptic loss
Yuan et al. (2002)
Laminin-γ2 MT1-MMP Structural stability of the synapse Koshikawa et al. (2005)Frontiers in Psychiatry  |  Neurodegenerative Diseases    October 2010  | Volume 1  | Article 130  |  4
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Expanded Disability Status Scale (Kurtzke, 1983; Fernandes et al., 
2009). Increased C-1562T risk for MS was also noted in a recent Polish 
population study (Mirowska-Guzel et al., 2009).
MMp inhibitors have shown proMise toward Ms 
treatMent
Evidence from previously published studies suggests that overall, 
MMPs may play a detrimental role in MS. For example, TIMP-1 
overexpression  has  been  linked  to  a  reduction  in  the  infiltra-
tion of leukocytes as well as a reduced disease score on day 18 
(Althoff et al., 2010). In related work, C57/Bl6 mice deficient in 
tissue inhibitor of metalloproteinases-1 (TIMP-1) show increased 
myelin pathology as compared to their wild type counterparts fol-
lowing MOG induced EAE (Crocker et al., 2006). Whether synaptic 
changes occurred and were also limited is unknown. Of interest, 
while TIMP-1 expression may typically increase in EAE and play 
a myelin protective role, TIMP-1 levels do not generally increase 
in MS (Crocker et al., 2006).
Studies using MMP inhibitors also suggest that these enzymes 
may contribute to disease pathology. For example, minocycline, an 
inhibitor that penetrates the brain and spinal cord, has been shown 
to suppress ongoing disease activity and to limit disease progression 
in a study that examined MOG immunized rats (Popovic et al., 
2002). While minocycline has effects additional to the inhibition 
of MMP activity and expression, the authors noted that MMP-2 
expression was increased in areas of inflammation in sham treated 
animals and that such expression was indeed reduced in minocycline 
treated animals (Popovic et al., 2002). They also pointed out that 
models of rheumatoid arthritis support the view that inhibition of 
MMP expression is at least in part responsible for the clinical efficacy 
of minocycline. Other animal studies also support a role for minocy-
cline as a therapeutic agent. For example, when given in combination 
with glatiramer acetate or interferon-γ, minocycline therapy was 
associated with decreased inflammation, demyelination and axonal 
injury in MOG induced murine EAE (Giuliani et al., 2005a,b). In 
animal studies focused on particular MMPs, however, the situation 
is more complex. Studies suggest that while inhibition of family 
members including MMP-7 and -9 might benefit disease severity 
(Yong et al., 2007; Buhler et al., 2009), inhibition of MMP-12 might 
actually be detrimental (Weaver et al., 2005; Goncalves DaSilva and 
Yong, 2009). Thus, in the future it might be beneficial to design 
inhibitors that are somewhat selective (Yong et al., 2007).
Work from human studies also suggests that general inhibi-
tion of MMP activity might hold promise. A recent pilot study has 
demonstrated that minocycline could reduce gadolinium enhanc-
ing MRI lesions in MS within 2 weeks of treatment (Metz et al., 
2004). Moreover, after 24 months of therapy, patients remained 
stable. In related work, estriol has been shown to reduce   gadolinium 
  enhancing lesions and to reduce levels of MMP-9 (Sicotte et al., 
2002; Gold et al., 2009). In other work consistent with a role for 
MMPs in MS, interferon-β (IFN-β was shown to reduce MMP 
secretion and T cell migration (Leppert et al., 1996; Stuve et al., 
1996). IFN therapy has also been linked to reduced peripheral 
blood mRNA for MMP-8, -9 and -19 (Bernal et al., 2009), and 
with decreased mRNA for MMP-7 in relapsing remitting, but not 
chronic progressive, patients (Galboiz et al., 2001). In a related 
study, IFN-β was associated with an early and sustained (24 month) 
that the regulated processing of synaptic CAMs with subsequent 
effects on synaptic structure, likely plays a role (Tian et al., 2007; 
Conant et al., 2010).
elevated levels of MMps May interfere with MMp-dependent 
learning, and when sustained, May contribute to  
synaptic injury
While physiological release of MMPs may enhance synaptic trans-
mission, substantially elevated levels of these enzymes, as may occur 
with MS, might have different effects. Elevated levels might cause 
processes to which MMPs contribute, such as LTP, to go awry. In 
addition, high levels of MMPs might be neurotoxic. This latter pos-
sibility is supported by a variety of studies. For example, we have 
shown that high levels of MMP-1 were toxic to neurons in organo-
typic and dissociated cultures (Vos et al., 2000). Moreover, several 
investigators have shown that MMP-9 may be neurotoxic (Gu et al., 
2002; Jourquin et al., 2003; Thornton et al., 2008). In one study, 
recombinant MMP-9 caused pyramidal cell toxicity in hippocampal 
cultures (Jourquin et al., 2003). Published studies also suggest that 
the synapse may be vulnerable to MMP mediated toxicity. We noted 
that long term treatment of hippocampal neurons with MMP-7 led 
to a reduction in synaptic stability as determined by reductions in 
post-synaptic density length and terminal area (Szklarczyk et al., 
2007a). And in a recent study of traumatic brain injury, it was noted 
that synapse loss, measured by reductions in synaptophysin, was 
prevented by an MMP inhibitor (Ding et al., 2009).
varied MMps May be elevated in association with  
Ms and eae
Elevated levels of select MMPs, including MMP-2, 7, -9, and -12, 
have been detected in association with MS (Maeda and Sobel, 1996; 
Cossins et al., 1997; Lindberg et al., 2001; Vos et al., 2003; Diaz-
Sanchez et al., 2006), and elevated MMP levels have been corre-
lated with disease severity and disability (Benesova et al., 2009). 
Elevated levels of MMPs including MMP-7 and MMP-9 have also 
been detected in EAE. In one study of adoptive transfer EAE, mRNA 
for MMP-7 was increased with maximum levels at peak disease. 
Levels of mRNA for MMP-9 were also elevated, while those of 
MMP-2 or -3 were not (Kieseier et al., 1998). The transcriptional 
expression of MMPs has also been examined in MS. In one study 
of post-mortem MS brain tissue by real-time polymerase chain 
reaction, it was noted that the mRNA expression of MMP-7 and 
-9 was upregulated throughout all stages of lesion formation with 
active inflammation (Lindberg et al., 2001). In this study, mRNA 
levels of while MMP-2,-3, and tumor necrosis factor (TNF)-alpha-
converting-enzyme were not elevated. In a more recent study of 
mRNA in peripheral blood leukocytes from MS patients, MMP-7 
and MT1-MMP were upregulated in relapsing remitting or chronic 
progressive patients as compared to controls. In this study, MMP-9 
levels were not increased.
In work related to the question of whether MMPs are increased 
with MS, the possibility that polymorphisms influencing MMP 
expression may alter disease risk and/or severity has been exam-
ined. Fernandes and colleagues looked at the C-1562T polymorphism, 
which leads to increased MMP-9 expression, in a large cohort of 
patients (165 MS, 191 controls) and found that the polymorphism 
was associated with increased disease severity as assessed by the www.frontiersin.org  October 2010  | Volume 1  | Article 130  |  5
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